The Fight Against HCV

FOR U.S. HEALTHCARE PROFESSIONALS

ABBVIE MEDICAL AFFAIRS

In 2013, viral hepatitis was a leading cause of death worldwide. More than 90% of this burden is due to the hepatitis B virus (HBV) and hepatitis C virus (HCV).¹

The 2014 World Health Assembly asked the World Health Organization (WHO) to explore how to eliminate HCV. In response, the WHO set 2030 targets for diagnosis, treatment, incidence, and mortality that would achieve the goal of eliminating HCV as a global health burden. Below are more details about the mission—as well as how we all can help make this important mission a reality.

Hepatitis C Elimination in the US

Learn what HCV experts are doing to eliminate the disease in the United States.

Explore

The treater landscape is changing

The paradigm is shifting toward more nonspecialist providers treating HCV²
Remote specialist oversight could mean more patients treated by primary care providers, with fewer specialist resources used³

Hepatitis C Elimination in the US

The HCV landscape has changed.

Watch

The WHO report on eliminating hepatitis C.

MappingHepC.com shows you where patients are located and provides characteristics of diagnosed RNA+ patients.

Explore

HCV and injection drug use.

Find a syringe exchange program near you.

Working with the CDC to start a syringe services program.

References:
1. Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081-1088. doi:10.1016/S0140-6736(16)30579-7
2. Butt AA, Yan P, Lo Re IV, Shaikh OS, Ross DB. Trends in treatment uptake and provider specialty for hepatitis C virus (HCV) infection in the Veterans Affairs healthcare system: results from the electronically retrieved cohort of HCV-infected veterans (ERCHIVES). Clin Infect Dis. 2019;68(5):857-859. doi:10.1093/cid/ciy697
3. Thomas J, Thompson H, Wu T, et al. Direct-acting antiviral therapy in primary care following non-real time, remote specialist review–a practical solution to scaling up HCV therapy [Abstract 474]. Hepatology. 2018;68(suppl 1):283-284. doi:10.1002/hep.30257